CLINICAL STAGE IV GASTRIC CANCER AJCC V8

This study tested a combination of two drugs, berzosertib and irinotecan, in 17 people with advanced stomach or gastroesophageal junction cancer that had a specific genetic change (TP53 mutation). The goal was to see if the combination could shrink tumors. Unfortunately, no patie…

This early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (which blocks a DNA repair enzyme)—in people with advanced solid tumors that have a HER2 mutation. The goal is to find the safest dose and see if the combo wo…

This early-phase study tests a new drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially bladder cancer. The main goals are to find the safest dose and understand side effects. About 7…

This study tests whether adding radiation therapy to standard chemotherapy helps people with HER2-negative esophageal or stomach cancer that has spread to a few other spots in the body (oligometastatic). About 314 participants will receive either chemotherapy alone or chemotherap…

This early-phase trial tests the safety and best dose of sonidegib combined with the immunotherapy pembrolizumab in people with advanced solid tumors that have spread. The goal is to see if this drug pair can shrink tumors or slow their growth. About 36 adults with cancers like m…

This early-phase trial is testing the safety and best dose of the chemotherapy drug paclitaxel when given directly into the abdomen (intraperitoneal) for people with advanced stomach or gastroesophageal cancer that has spread to the lining of the abdomen. The study includes 27 pa…

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. The goal is to track how cancer changes over time and during treatment. Researchers hope this will help them understand why some cancers resist therapy a…